Closing the Gap: the Real-World Risk of Serious Infections With Vedolizumab in Comparison With Anti-TNF Therapy in Inflammatory Bowel Disease
- PMID: 34022455
- DOI: 10.1016/j.cgh.2021.05.026
Closing the Gap: the Real-World Risk of Serious Infections With Vedolizumab in Comparison With Anti-TNF Therapy in Inflammatory Bowel Disease
Comment on
-
Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease.Clin Gastroenterol Hepatol. 2022 Feb;20(2):314-324.e16. doi: 10.1016/j.cgh.2020.12.030. Epub 2020 Dec 30. Clin Gastroenterol Hepatol. 2022. PMID: 33387667
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous